Develops precision-targeted oral drug formulations that restore endogenous hormone release from nutrient-sensing gastrointestinal cells to treat and prevent metabolic disorders such as obesity. Lead oral glucose formulation is in Phase 2, being evaluated for chronic weight management in people with obesity and for improving glucose tolerance in individuals with prediabetes.